Abstract
Cigarette smoking is the main risk factor for chronic obstructive pulmonary disease (COPD). However, not all smokers develop clinically significant symptoms. It is recognized that multiple genetic factors and genotype-byenvironment interactions are involved in the development of COPD. Remarkable progress in the genetic knowledge and technology has changed the approaches used to identify candidate genes. Genome-wide linkage analyses have revealed several chromosomal regions linked to COPD phenotypes. The recently introduced gene expression profiling techniques have identified hundreds of genes differentially expressed in COPD. Case-control association studies have reported more than 30 polymorphisms related to the susceptibility to COPD. However, the replication of these results has been limited. In this review, we present our current understanding of the genetic basis of COPD and the findings of genetic studies. The advantages and limitations of the different genetic approaches are also discussed. The increasing knowledge of the COPD genetics combined with a better understanding of its clinical and pathological heterogeneity will have a great potential to change views on the pathogenesis and diagnosis, and even to influence the clinical management.
Keywords: Association study, chronic obstructive pulmonary disease, linkage, and polymorphism
Current Respiratory Medicine Reviews
Title: Genetics of Chronic Obstructive Pulmonary Disease
Volume: 1 Issue: 3
Author(s): Ahmed E. Hegab, Tohru Sakamoto and Kiyohisa Sekizawa
Affiliation:
Keywords: Association study, chronic obstructive pulmonary disease, linkage, and polymorphism
Abstract: Cigarette smoking is the main risk factor for chronic obstructive pulmonary disease (COPD). However, not all smokers develop clinically significant symptoms. It is recognized that multiple genetic factors and genotype-byenvironment interactions are involved in the development of COPD. Remarkable progress in the genetic knowledge and technology has changed the approaches used to identify candidate genes. Genome-wide linkage analyses have revealed several chromosomal regions linked to COPD phenotypes. The recently introduced gene expression profiling techniques have identified hundreds of genes differentially expressed in COPD. Case-control association studies have reported more than 30 polymorphisms related to the susceptibility to COPD. However, the replication of these results has been limited. In this review, we present our current understanding of the genetic basis of COPD and the findings of genetic studies. The advantages and limitations of the different genetic approaches are also discussed. The increasing knowledge of the COPD genetics combined with a better understanding of its clinical and pathological heterogeneity will have a great potential to change views on the pathogenesis and diagnosis, and even to influence the clinical management.
Export Options
About this article
Cite this article as:
Hegab E. Ahmed, Sakamoto Tohru and Sekizawa Kiyohisa, Genetics of Chronic Obstructive Pulmonary Disease, Current Respiratory Medicine Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339805774598045
DOI https://dx.doi.org/10.2174/157339805774598045 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Immunotherapeutic Strategies for Invasive Fungal Disease
Current Drug Targets - Cardiovascular & Hematological Disorders The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design JAK3 Inhibitors in Organ Transplantation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Advances in the Systemic Treatment of Neuroendocrine Tumors in the Era of Molecular Therapy
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews A Compendium of Volatile Organic Compounds (VOCs) Released By Human Cell Lines
Current Medicinal Chemistry NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Impact of Epigenetic Dietary Components on Cancer through Histone Modifications
Current Medicinal Chemistry Culture Supernatants from Lactobacillus plantarum Induce Necrosis on a Human Promyelocytic Leukemia Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Editorial: Looking Forward to Another Successful Year
Current Cancer Drug Targets The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Current Pharmaceutical Design